- Home
- LRCX vs ABBV Comparison
LRCX vs ABBV Comparison
Compare LRCX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRCX | ABBV |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7B | 400.9B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LRCX | ABBV |
|---|---|---|
| Price | $211.66 | $220.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 19 |
| Target Price | $241.79 | ★ $247.06 |
| AVG Volume (30 Days) | ★ 7.8M | 5.4M |
| Earning Date | 04-29-2026 | 04-13-2026 |
| Dividend Yield | 0.50% | ★ 3.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.50 | 2.36 |
| Revenue | $3,237,693,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $23.89 | $11.90 |
| Revenue Next Year | $24.37 | $8.24 |
| P/E Ratio | ★ $83.64 | $95.47 |
| Revenue Growth | ★ 51.74 | 8.57 |
| 52 Week Low | $57.97 | $164.39 |
| 52 Week High | $256.68 | $244.81 |
Technical Indicators
Market Signals| Indicator | LRCX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 39.82 |
| Support Level | $201.51 | $207.88 |
| Resistance Level | $254.28 | $231.00 |
| Average True Range (ATR) | 8.90 | 5.15 |
| MACD | -3.10 | -1.18 |
| Stochastic Oscillator | 22.09 | 1.87 |
Price Performance
Historical ComparisonAbout LRCX Lam Research Corporation
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.